Subscribe
shutterstock_1017347380_sundryphotography
sundryphotography / Shutterstock.com
10 October 2019Big PharmaSaman Javed

J&J invests $500m into global HIV and TB treatment

Johnson & Johnson (J&J) has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis (TB) across the world by 2030.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Big Pharma
Global Drug Facility adds new TB drug to its catalogue
31 October 2019   The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Big Pharma
Global Drug Facility adds new TB drug to its catalogue
31 October 2019   The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.

More on this story

Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Big Pharma
Global Drug Facility adds new TB drug to its catalogue
31 October 2019   The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility